Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

General Asked Questions

PS13-1310: HIV Prevention Projects for the Commonwealth of Puerto Rico and the U.S. Virgin Islands

  1. The FOA provides includes Enhanced HIV Testing requirements for CBOs providing testing in clinical and non-clinical testing settings. Our agency would like to provide testing in both CBO clinical and non-clinical settings, what is the HIV testing range for this scenario?
    1. An amended FOA will be uploaded to www.grants.gov and the PS13-1310 website soon. You can find specific language regarding HIV testing in CBO clinical and non-clinical settings on pages 9 and 29 of the amended FOA. If your organization is proposing to conduct enhanced HIV testing in a CBO clinical and non-clinical setting, enhanced HIV testing must be provided to a minimum of 600-900 members of the target population annually.
    2. The minimum range for the previously undiagnosed seropositivity rate remains the same, regardless of the setting in which your organization proposes to implement enhanced HIV testing.
  2. Is there a minimum number of interventions that our agency must implement for our Comprehensive and Innovative Client-Centered HIV Prevention Program?
    1. No, there is not a minimum number of interventions that must be implemented under your PS13-1310 Comprehensive and Innovative Client-Centered HIV Prevention Program (CICCHPP). However, your CICCHPP should include a combination of structural, behavioral and/or biomedical interventions that support maximum reach and optimal outcomes for the clients your organization serves. Organizations may elect to continue to implementing the effective behavioral intervention (EBI) for which you are currently funded to implement under PS08-803 as a component of your CICCHPP; however, the CICCHPP must respond to all programmatic requirements listed in the PS13-1310 FOA and directly align with the National HIV/AIDS Strategy (NHAS) and High –Impact HIV Prevention (HIP). Therefore, if your organization plans to continue with the implementation of the EBI(s) funded under PS08-803, you must first determine if the EBI is in alignment with NHAS and HIP. If the EBI does not align with the goals and objectives of NHAS and HIP, it is not eligible for inclusion in your PS13-1310 CICCHPP.
    2. For additional information, please refer to the PS13-1310 Overview of Combination Approaches presentation. https://www304.livemeeting.com/cc/cdc/view?id=KN7P24
  3. Does Personalized Cognitive Counseling (PCC) have to be implemented when we are conducting HIV testing during outreach events in the field?
    1. Answer: Applications submitted in response to PS13-1310, must address all requirements listed in the FOA. PCC is an intervention originally designed for MSM who have been tested before, told they were HIV negative, and then after being told they were HIV negative engaged in unprotected anal intercourse. However, PCC can and should be adapted for the target population(s) you are proposing to serve under PS13-1310. The intervention does take some time to administer and requires space for client privacy; therefore, if the time constraints associated with the implementation of PCC are a barrier to the implementation of the HIV testing component of your program, RESPECT maybe be implemented in replace of PCC, as appropriate.
 

 


 

Find an HIV testing site near you.

For additional HIV services, select the "More" tab.

Search location, such as: "Atlanta, GA", or "30033".

For more information on this widget, please visit www.aids.gov

Please contact hivwebmaster@cdc.gov with any comments, suggestions, or concerns.

Services








Syndicate This Content Podcast button Tell us what you think button CDC-INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO